Mylan N.V. and Upjohn Inc. - proposed merger


  • Mylan N.V.


  • Upjohn Inc.


The Australian Competition and Consumer Commission (ACCC) is seeking your views on the proposed combination of Mylan N.V. (Mylan) with a new entity (NewCo) comprised of Pfizer’s Upjohn Inc. division (Upjohn), including Greenstone LLC (the proposed transaction).

Mylan and Upjohn both supply cardiovascular, neurology & pain, psychiatry, urology and ophthalmology pharmaceutical products in Australia.

In order to address any potential competition concerns arising from the proposed transaction, Mylan has offered to divest 12 molecules where overlap exists with those supplied by Upjohn (the divestiture proposal) to an ACCC approved purchaser.

Market inquiries

Submissions are invited from interested parties regarding the proposed transaction. 

The closing date for submissions is 22 April 2020. Submissions should be forwarded electronically (preferably in PDF format) to with the title "Submissions re: Mylan N.V's proposed combination with Upjohn Inc. - attention Annalisa Heger/Adrian Hughes".

Following the closing date, queries regarding the ACCC's review may be addressed to Annalisa Heger/Adrian Hughes at For more details, please refer to the attached market inquiries letter.

Market inquiries

Document title Date


24/03/2020ACCC commenced review under the Merger Process Guidelines.
22/04/2020Closing date for submissions. The ACCC will place an indicative decision date here shortly.
04/06/2020ACCC awaiting further information from the parties. Former provisional date for announcement of ACCC's finding (11 June 2020) is delayed. ACCC will announce a proposed decision date in due course.

Project staff

  • Annalisa Heger
  • Adrian Hughes

Contact email